Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (27)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Jansen, R. H. L.
Right arrow Articles by Hillen, H. F. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jansen, R. H. L.
Right arrow Articles by Hillen, H. F. P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 9:109-111, 1998
© 1998 European Society for Medical Oncology

other

CD44v6 is not a prognostic factor in primary breast cancer

R. H. L. Jansen1, S. R. Joosten-Achjanie1, J. W. Arends2, A. Volovics3, P. S. G. J. Hupperets1, H. C. Schouten1 and H. F. P. Hillen1

1Department of Internal Medicine, University Hospital Maastricht the Netherlands
2Department of Pathology, University Hospital Maastricht the Netherlands
3Department of Methodology and Statistics, University Maastricht the Netherlands

Background: CD44 is an adhesion molecule and represents a highly variable family of isoforms. The isoform CD44v6 has been associated with metastasis formation and poor prognosis in animal models and human colon cancer. Results of studies in primary breast cancer are relatively small and contradictory.

Patients and methods: The immunohistochemical expression of CD44v6 was studied in a series of 338 patients with primary breast tumours, uniformly staged and treated in a single center with a long median follow-up of 128 months. The prognostic significance of CD44v6 as well as the correlation with several clinicopathological features were analysed.

Results: Two hundred nineteen of 338 (64.8%) of the breast cancers were CD44v6-positive (< 5% of tumour cells with positive staining). CD44v6 expression had no value for prognosticating disease-free or overall survival at this or any other cut-off point.

Conclusion: CD44v6 expression is not a prognostic factor in primary breast cancer.

CD44v6, primary breast cancer, prognostic factor


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
L. K. Diaz, X. Zhou, E. T. Wright, M. Cristofanilli, T. Smith, Y. Yang, N. Sneige, A. Sahin, and M. Z. Gilcrease
CD44 Expression Is Associated with Increased Survival in Node-Negative Invasive Breast Carcinoma
Clin. Cancer Res., May 1, 2005; 11(9): 3309 - 3314.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
C Faivre-Finn, A-M Bouvier-Benhamiche, J M Phelip, S Manfredi, V Dancourt, and J Faivre
Colon cancer in France: evidence for improvement in management and survival
Gut, July 1, 2002; 51(1): 60 - 64.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
I. Okamoto, H. Tsuiki, L. C. Kenyon, A. K. Godwin, D. R. Emlet, M. Holgado-Madruga, I. S. Lanham, C. J. Joynes, K. T. Vo, A. Guha, et al.
Proteolytic Cleavage of the CD44 Adhesion Molecule in Multiple Human Tumors
Am. J. Pathol., February 1, 2002; 160(2): 441 - 447.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
L Hebbard, A Steffen, V Zawadzki, C Fieber, N Howells, J Moll, H Ponta, M Hofmann, and J Sleeman
CD44 expression and regulation during mammary gland development and function
J. Cell Sci., January 7, 2000; 113(14): 2619 - 2630.
[Abstract] [PDF]

Home page
 JCOHome page
M. A. Dimopoulos, P. Panayiotidis, L. A. Moulopoulos, P. Sfikakis, and M. Dalakas
Waldenstrom’s Macroglobulinemia: Clinical Features, Complications, and Management
J. Clin. Oncol., January 5, 2000; 18(1): 214 - 214.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.